Staff Research Rounds - Dr Teerawattananon & Dr Isaranuwatchai

Date:

Mon, 10 July 2023

Time:

4:30pm – 5:30pm [Singapore [GMT +8]

Location:

Seminar Room 2, Level 8
Tahir Foundation Building (MD1)
National University of Singapore
12 Science Drive 2, Singapore 117549

Details:

You are cordially invited to the ON-SITE SSHSPH Staff Research Round. We look forward to your attendance and we hope for an interesting discussion.

Refreshments will be provided at 4pm, do drop by to hang out for a bit before the session starts.

We will also be having a Lucky Draw at the end of the session, register yourself and stand a chance to win a special prize!

*Only Attendees will be included in the Lucky draw*

Abstract:

There has been lots of debate regarding an optimum value of cost-effectiveness threshold around the world. Many governments, for examples, in the United Kingdom and Thailand receive challenges whether the current CET used are too low and that their CET should be increased. To our knowledge, Thailand is the only country which has explicit CET and has increased the CET during the past 15 years. Therefore, Thailand is in a unique position to help answer the question of what happened when CET was increased. The findings from this study can assist in the discussion of whether and how CET values should be increased. Health Intervention and Technology Assessment Program (HITAP) in collaboration with Saw Swee Hock School of Public Health, National University of Singapore and the Hitotsubashi Institute for Advanced Study in Japan, was commissioned by the National Drug Subcommittee to answer the question of “What are the Impacts of Increasing Cost-effectiveness Threshold?” to assist in the discussion of whether or not Thailand’s current CET should be increased. The study objectives were to explore the impact of increasing cost-effectiveness threshold (CET) on the submitted drug price (published in economic evaluation reports) and the decision to include high-cost drugs in the National List of Essential Medicine (NLEM) in Thailand. Retrospective secondary data analysis using data from published economic evaluation reports being reviewed by the National Drug Subcommittee in the past 13 years.

Speakers:

Dr Yot Teerawattananon
Founding Leader, Health Intervention and Technology Assessment Program, Thailand

Dr Yot Teerawattananon is a Founding Leader of the HITAP of the Thai Ministry of Public Health of which its works have been used to inform health benefit package of the Universal Health Coverage Scheme. He previously served as a medical doctor and director of Pong Hospital in northern Thailand before completing his Ph.D. in Health Economics from UK in 2006. Dr Yot has gone on to provide technical advice to many national and international agencies such as the Gates Foundation, WHO, World Bank, Asian Development Bank and the Centre for Global Development (CGD), giving him a broad knowledge of key is-sues in global health. He has also worked in Bhutan, India, Indonesia, Kenya, Myanmar, Nepal, Sri Lanka, the Philippines, and Vietnam. He is also in the World Health Report 2013 of the World Health Organization as a role model organization informing policy decisions to support Universal Health Coverage in resource limited settings. Dr Yot is also one of the founders of HTAsiaLink a regional network comprising of governmental health technology assessment agencies throughout Asia.

Dr Wanrudee Isaranuwatchai
Program Leader & Senior Researcher Health Intervention and Technology Assessment Program
Thailand

Dr Wanrudee Isaranuwatchai is a Program Leader and Senior Researcher of the Health Intervention and Technology Assessment Program (HITAP), which is a semi-autonomous research institute of Thailand’s Ministry of Public Health in Bangkok, Thailand. She is also an Affiliated Scientist at St. Michael’s Hospital, and an Assistant Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, in Canada. Her research focuses on how to apply health economics and health technology assessment (HTA) in the real-world setting as well as how to advance methods in economic evaluation. She has collaborated with researchers, health professionals, and policy-makers in various areas to help communicate the value of health initiatives using economic evidence around the world (e.g., Bhutan, Kenya, and Canada). She has contributed to the training on HTA to support universal health coverage (UHC) and health systems in Asia, Africa, and North America. Dr Isaranuwatchai is dedicated to the creation and use of evidence in healthcare decision making.